{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '8.2.4.', 'Clinical Safety Laboratory Assessments', 'Laboratory assessments will be tested at a central laboratory facility. Any clinically significant', 'abnormal results should be followed until resolution or stabilization.', 'All protocol-required laboratory assessments, as defined in Section 10.2 (Appendix 2), must be', 'conducted in accordance with the laboratory manual and the SoA (Section 1.3).', 'The Investigator must review the laboratory report, document this review, and record any', 'clinically relevant changes occurring during the study in the AE section of the eCRF. The', 'laboratory reports must be filed with the source documents.', 'Clinically significant abnormal laboratory findings associated with the underlying disease are not', 'considered AEs unless they are judged by the Investigator to be more severe than expected for', \"the patient's condition.\", 'If such values do not return to normal/baseline within a period of time judged reasonable by the', 'Investigator, the etiology should be identified and the Sponsor notified.', '8.2.4.1.', 'Urinalysis and Urine Chemistry', 'Urine samples will be analyzed for the parameters listed in Section 10.2 (Appendix 2). A', 'microscopic examination of urine samples will be performed if the results of the macroscopic', 'analysis are abnormal.', '8.2.4.2.', 'Virus Serology', 'Human immunodeficiency virus testing for HIV-1 and HIV-2 is required of all patients prior to', 'enrollment. Patients who are HIV positive will not be enrolled.', '8.2.4.3.', 'Immunogenicity Assessments', 'Blood samples will be collected to test for presence of ADAs to ravulizumab in serum prior to', 'study drug administration. Further characterization of antibody responses may be conducted as', 'appropriate, including ADA titer, binding and neutralizing antibodies, PK/PD, safety, and', 'activity of ravulizumab. Antibodies to ravulizumab will be evaluated in serum samples collected', 'from all patients according to the SoA (Section 1.3). Serum samples will be screened for', 'antibodies binding to ravulizumab and the titer of confirmed positive samples will be reported.', 'The detection and characterization of antibodies to ravulizumab will be performed using a', 'validated assay by or under the supervision of the Sponsor.', 'Detailed instructions on the procedure for collecting, processing, storing, and shipping serum', 'samples for immunogenicity analysis will be provided in the laboratory manual.', '8.2.5.', 'Suicidal Risk Monitoring', '8.2.5.1.', 'Columbia-Suicidal Severity Rating Scale', 'The Columbia-Suicide Severity Rating Scale (C-SSRS; Section 10.14 [Appendix 14] and', 'Section 10.15 [Appendix 15]) is a validated questionnaire used extensively across primary care,', 'clinical practice, surveillance, research, and institutional settings to assess suicidal ideation and', 'behavior (Posner, 2011). The C-SSRS will be administered by the Investigator or a properly', 'Page 56 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'trained designee. The C-SSRS will be assessed for both lifetime and past 1 year (12 months) as', 'specified in the SoA (Section 1.3). The C-SSRS is being implemented to ensure that patients', 'who are experiencing suicidal ideation or behavior are properly recognized and adequately', 'managed.', '8.3.', 'Adverse Events and Serious Adverse Events', 'Adverse events will be reported to the Investigator or qualified designee by the patient (or when', \"appropriate, by a caregiver, surrogate, or the patient's legally authorized representative).\", 'The Investigator or qualified designees are responsible for detecting, documenting, and recording', 'events that meet the definition of an AE or SAE, and remain responsible for following up events', 'that are serious, considered related to the study drug or study procedures; or that caused the', 'patient to discontinue the study drug (Section? 7).', 'Definitions and procedures for recording, evaluating, follow-up, and reporting AEs and SAEs are', 'outlined in Section 10.3 (Appendix 3).', '8.3.1.', 'Time Period and Frequency for Collecting Adverse Event and Serious Adverse', 'Event Information', 'All AEs will be collected from the signing of the ICF until 8 weeks after the last dose of study', 'drug is administered.', 'Medical occurrences that begin before the start of study drug but after obtaining informed', 'consent must be recorded in the AE case report form (CRF) as AEs and not in the Medical', 'History/Current Medical Conditions CRF.', 'All SAEs will be recorded and reported to the Sponsor or designee within 24 hours, as indicated', 'in Section 10.3 (Appendix 3). The investigator will submit any updated SAE data to the Sponsor', 'within 24 hours of awareness.', 'Investigators are not obligated to actively seek AEs or SAEs after the conclusion of study', 'participation. However, if the Investigator learns of any SAE, including a death, at any time after', 'a patient has been discharged from the study, regardless of whether or not the event is related to', 'the study drug, the Investigator must promptly notify the Sponsor.', 'The method of recording, evaluating, and assessing causality of AE and SAE and the procedures', 'for completing and transmitting SAE reports are provided in Section 10.3 (Appendix 3).', '8.3.2.', 'Method of Detecting Adverse Events and Serious Adverse Events', 'Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and', 'nonleading verbal questioning of the patient is the preferred method to inquire about', 'AE occurrences.', '8.3.3.', 'Follow-up of Adverse Events and Serious Adverse Events', 'After the initial AE/SAE report, the Investigator is required to proactively follow each patient at', 'subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event is', 'otherwise explained, or the patient is lost to follow-up (as defined in Section 7.2). Further', 'information on follow-up procedures is given in Section 10.3 (Appendix 3).', 'Page 57 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}